CFR Pharmaceuticals Announces Exemption From the Takeover

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CFR Pharmaceuticals Announces Exemption From the Takeover Regulation Panel ("TRP") and Confirmation That the Termination Agreement Concluded on 7 February 2014 ("Termination Agreement") is Now Effective

SANTIAGO, Chile, Feb. 13, 2014 (GLOBE NEWSWIRE) -- CFR Pharmaceuticals S.A. (SSE:CFR), the Chilean multinational emerging markets pharmaceutical company, leader in specialties and prescription medicines, refers shareholders to the announcement released on the Stock Exchange News Service of the JSE Limited by Adcock Ingram and CFR ("the Parties") on Friday, February 7, 2014, advising that the Parties had entered into a Termination Agreement providing for the consensual termination of the Transaction Implementation Agreement concluded between the Parties on 11 September 2013, as amended ("TIA") and the termination of the scheme of arrangement proposed between Adcock Ingram and the holders of Adcock Ingram ordinary shares (other than the holders of A and B ordinary shares and treasury shares) in relation to the CFR offer ("Scheme").

In terms of the Termination Agreement, the termination of the TIA and the Scheme was conditional upon receipt of written exemption from the TRP from, among other things, the application of regulation 101 (2) of the Companies Regulations, 2011.

Shareholders are advised that CFR has now received the requisite exemption from the TRP and, accordingly, the Termination Agreement is now effective.

About CFR

CFR is a multinational pharmaceutical corporation with a leading position in Latin America and operations in 15 countries in that region. It is the leading pharmaceutical company in Chile, Colombia and Peru, and also has presence in Vietnam, Canada and the United Kingdom, focusing on the research, development, production and sale of branded specialty pharmaceutical products, complex Injectables, and OTC products. CFR has its origins in 1922 and it was listed on the Santiago Stock Exchange in 2011 on a successful IPO –more than ten times oversubscribed– becoming the only publicly traded pan-Latin American pharmaceutical company. CFR has a market capitalization of US$2 billion, employs over 7,000 people including 2,000 sales representatives. CFR's growth strategy focuses on markets in the Americas, Europe and Asia with expansion plans into emerging markets with high growth potential.

GOVERNING LAW AND JURISDICTION

The Scheme is governed by the laws of South Africa. Each of CFR and Adcock Ingram has consented to the non-exclusive jurisdiction of the South Gauteng High Court, Johannesburg.

None of this press release, the Circular, the Supplementary Circular, the Prospectus or the Joint Cautionary Announcement, are intended to, and do not, constitute, or form part of, an offer to sell or an invitation to purchase or subscribe for any securities or a solicitation of any vote or approval in any jurisdiction. None of this press release, the Circular, the Supplementary Circular, the Prospectus or the Joint Cautionary Announcement, constitutes a prospectus or a prospectus equivalent document. Investors are advised to read carefully the Circular and the Supplementary Circular for the full terms and conditions of the Scheme. Any decision to accept the Scheme or other response to the proposals should be made only on the basis of the information contained in the Circular and the Supplementary Circular.

This press release is made in connection of, an offer for the securities of a South African company by means of the Scheme. The offer is subject to disclosure requirements under South African law that are different from those of the United States and Chile. Financial statements included in the Scheme or the Prospectus have been prepared in accordance with South African accounting standards that may not be comparable to the financial statements of United States or Chilean companies.

It may be difficult for you to enforce your rights and any claim you may have arising under the United States federal securities laws, since Adcock Ingram is located in South Africa, and all of its officers and directors reside outside of the United States. You may not be able to sue Adcock Ingram or its officers or directors in a foreign court, including South African courts, for violations of the Unites States securities laws. It may be difficult to compel Adcock Ingram and its affiliates to subject themselves to a United States court's judgment.

You should be aware that CFR may purchase ordinary shares of Adcock Ingram otherwise than under the offer, such as in open market or privately negotiated purchases.

FORWARD-LOOKING STATEMENTS

This press release, the Circular, the Prospectus and the Announcement include forward-looking statements with respect to the financial condition, results of operations and businesses of CFR and Adcock Ingram and certain plans and objectives of the boards of CFR and Adcock Ingram with respect to them. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as "anticipate", "expect", "estimate", "intend", "plan", "goal", "believe", "will", "may", "should", "would", "could", or other words of similar meaning. These statements are based on assumptions and assessments made by the boards of CFR and Adcock Ingram in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe appropriate. By their nature, forward-looking statements involve risk and uncertainty, because they relate to events and depend on circumstances that will occur in the future and the factors described in the context of such forward-looking statements in this announcement could cause actual results and developments to differ materially from those expressed in or implied by such forward-looking statements. These risks and uncertainties include, among others, the risk that the Scheme is not completed, including the risk that required shareholder and regulatory approvals for the Scheme may not be obtained; diversion of management's attention away from other business concerns; the risks associated with the development, generally, of the combined company's overall strategic objectives; the ability of the combined company to build additional value in its business; the existence of unanticipated technical, commercial or other setbacks related to the combined company's products and services; and the other risks set forth in the Prospectus. The combined company may not successfully integrate the operations of CFR and Adcock Ingram in a timely manner, or at all, and the combined company may not realize the anticipated benefits or synergies of the Scheme.

Enquiries Deneb Schiele Head of Investor Relations Phone +562 2350 5320 Email

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Busch Gardens' Holiday Extravaganza Lights Up 2026

Updated Category News Views 30

A Dazzling Holiday Transformation Awaits Forget the mundane holiday light displays. Busch Gardens is cranking it up a notch with their annual Christmas Town spectacle, kicking off on November 13. With two parks—Tampa Bay and Williamsburg—each delivering a unique experience, prepare for an immersive dive into holiday cheer that's packed with glitz, entertainment, and,...

Continue Reading
Concurrence Expands Reach With Microsoft Marketplace

Updated Category News Views 50

Concurrence's Big Move into Microsoft's Court From the bustling streets of New York to the mighty tech avenues of Seattle, Concurrence is making waves that could leave a whale-sized impact on the healthcare sector. As of today, their Health World Model and snazzy AI agents have entered the Microsoft Marketplace, marking a significant leap forward. For the uninitiated,...

Continue Reading
Reducto Office Transforms Document Editing with AI

Updated Category News Views 30

AI Meets Full-Fidelity Document Editing Gone are the days when AI could only analyze documents. With Reducto Office's latest plugin, the AI's stepping right into the editing game. For free, they say! Built smack-dab into ChatGPT and Codex, this plugin lets users work their AI magic on Word docs, PowerPoint presentations, and Excel spreadsheets. And the kicker? You can see...

Continue Reading
Entangled 2026 Summit: Driving Quantum, AI, & Biotech Synergy

Updated Category News Views 20

What's Brewing at Entangled 2026? Innovation's got a new haunt come November, and it’s sprouting right in Cambridge's Kendall Square. LabCentral, C10 Labs, and Innovation Centre Denmark Boston have concocted something here for the curious minds: Entangled 2026. Picture over 250 movers and shakers from biotech, deep tech, investment, academia, and more, gathering under...

Continue Reading
Celebrate Dr. David Neff's Healthcare Legacy

Updated Category News Views 107

An Icon in Medicine and Innovation Dr. David R. Neff's recognition as a Pinnacle Lifetime Member marks a storied journey through medicine and healthcare innovation. Decades of Dedication to Patient Care For over 45 years, Neff carved out a niche in medicine that few can parallel. His overarching focus on infectious disease, cancer, and more represents a holistic approach...

Continue Reading
Arctic Wolf Leads in AI SOC: A 2026 Game Changer

Updated Category News Views 45

Leading the Pack with AI-Powered Security In the world of cybersecurity, where every day feels like a battlefield, Arctic Wolf has clawed its way to the top spot in the Q4 2026 QKS SPARK Matrix™ for AI SOC Automation. This recognition doesn't just highlight their prowess in handling security operations; it underscores their relentless commitment to infusing AI...

Continue Reading
Pozdeutinurad Phase 3 Success Impact on Sobi and Market

Updated Category News Views 60

Pozdeutinurad's Phase 3 Triumph Ah, the life of biotech—constant ups and downs, but when you hit a homerun, it feels like the market stands still for a second. Pozdeutinurad's recent Phase 3 REDUCE-2 study results are one of those moments for Swedish Orphan Biovitrum AB, or Sobi for short. This study showed some seriously compelling data: clinically meaningful and...

Continue Reading
xTool X1: Redefining Laser Fabrication for Makers

Updated Category News Views 140

The Next Generation of Laser Fabrication Whenever a new gizmo hits the market, it's usually just an upgrade in disguise—faster, shinier, a touch more wattage. Not this time. xTool shook things up by rolling out the X1, a laser platform that gets what small businesses and makers truly crave: versatility and long-lasting potential. This bad boy does more than engrave; it...

Continue Reading
Tiny Fish Revolutionizes Vertebrate Gene Studies

Updated Category News Views 34

From Small Fish to Big Discoveries: Meet Danionella cerebrum Who would've thought a diminutive fish with a see-through body would give a jolt to the study of vertebrate genomes? Thanks to Danionella cerebrum, researchers at the Whitehead Institute have created the very first complete whole-body single-cell atlas of an adult vertebrate. Forget the Wall Street clamor for a...

Continue Reading
A. O. Smith Reports Q3 2026: A Strategic Shift

Updated Category News Views 22

A. O. Smith Navigates Change in Third Quarter 2026 It's been a gritty third quarter for A. O. Smith, as the company maneuvers through domestic challenges and crafts a strategic future with international tweaks. They've hammered out $941 million in sales but found themselves grappling with net earnings dipping to $126 million, or $0.93 per diluted share, a mere blip from...

Continue Reading

Top 5 Most Recently Viewed Articles

ParaZero Secures Ministry of Defense Approval for HALO System

Updated Category News Views 126

ParaZero Technologies Achieves Major Approval for HALO System ParaZero Technologies Ltd. (Nasdaq: PRZO) has announced a significant milestone by receiving official approval from the Israeli Defense Export Controls Agency (DECA), part of the Ministry of Defense, for its advanced HALO Precision Airdrop System for drones. This groundbreaking approval marks a crucial step in...

Continue Reading
Innovative Partnership Transforms Ministry Education with AI

Updated Category News Views 235

Innovative Partnership Enhances Ministry Education Subsplash, the creators behind the transformative tool Pulpit AI, have recently entered a promising partnership with Southeastern University Barnett College of Ministry & Theology (SEU). With this collaboration, they aim to equip students and aspiring pastors with advanced tools to enhance their workflow and deliver...

Continue Reading
PennantPark Investment Corporation Prepares for Q4 2024 Earnings

Updated Category News Views 59

PennantPark Investment Corporation took a swing at the market back in late 2024. They announced their earnings for the fourth quarter ending September 30, and traders were buzzing about it. The report was slated to hit the wires on November 25, but you know how these things go; everyone had opinions before it even dropped. PennantPark’s Earnings: A Catalyst or a Cliff?...

Continue Reading
Key Details on Lockheed Martin's Class Action Lawsuit

Updated Category News Views 174

Understanding the Class Action Lawsuit Against Lockheed Martin Corporation Lockheed Martin Corporation has been notified of a class action securities lawsuit aimed at protecting the interests of its investors. This development is significant for shareholders looking to understand their rights and potential recourse. The firm Levi & Korsinsky is representing investors in...

Continue Reading
CPKC Announces Quarterly Dividend for Shareholders

Updated Category News Views 51

CPKC Declares Quarterly Dividend The Board of Directors of Canadian Pacific Kansas City Limited (TSX: CP) has announced a quarterly dividend of $0.19 per share for all outstanding common shares. This declaration marks an important decision for the company and its shareholders, reflecting CPKC's robust financial health and commitment to returning value to investors....

Continue Reading